Abstract:Background:JAK2 V617F mutation (mut) in acute myeloid leukemia (AML) is rare. We describe the clinicopathologic findings of a single-institution series of 11 de novo AML cases with JAK2 V617. Methods: We identified cases of de novo AML with JAK2 V617F over a 10-year period. We reviewed diagnostic peripheral blood and bone marrow (BM) morphologic, cytogenetic, and molecular studies, including next-generation sequencing. The control group consisted of 12 patients with JAK2 wild-type (wt) AML matched for age, sex, and diagnosis. Results: We identified 11 patients (0.5%) with JAK2 V617F, with a median age at diagnosis of 72.5 years (range, 36-90 years). Ten neoplasms were classified as AML with myelodysplasia-related changes and 1 as AML with t(8;21)(q22;q22). All JAK2mut AML cases showed at least bilineage dysplasia, 7 of 11 showed fibrosis, 8 of 11 had an abnormal karyotype, and 5 had deletions or monosomy of chromosomes 5 and 7. Using the European LeukemiaNet (ELN) classification, 9 patients (82%) with JAK2mut AML were intermediate-2 and adverse risk. Cases of JAK2mut AML did not have mutations in other activating signaling pathways (P=.013); 7 (64%) showed additional mutations in at least one gene involving DNA methylation and/or epigenetic modification. Patients with JAK2mut AML had a significantly higher median BM granulocyte percentage (12% vs 3.5%; P=.006) and a higher frequency of ELN intermediate-2 and adverse risk cytogenetics (P=.04) compared with those with JAK2wt AML. JAK2mut AML showed higher circulating blasts, but this difference was not significant (17% vs 5.5%; P=not significant). No difference was seen in the median overall survival rate of patients with JAK2mut AML versus those with JAK2wt AML (14 vs 13.5 months, respectively). Conclusions: De novo JAK2mut AML is rare and frequently found in patients with dysplasia, BM fibrosis, and abnormal karyotype with intermediate- or high-risk features; gene mutations in DNA methylation and epigenetic-modifying pathways; and absence of gene mutations in activating signaling pathways.

Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia

Roles of T875N Somatic Mutation in the Activity, Structural Stability of JAK2 and the Transformation of OCI-AML3 Cells.

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia.

Roles of Germline JAK2 Activation Mutation JAK2 V625F in the Pathology of Myeloproliferative Neoplasms

Disruption of R867 and Y613 Interaction Plays Key Roles in JAK2 R867Q Mutation Caused Acute Leukemia.

Effects of JAK2 V556F Mutation on the JAK2's Activity, Structural Stability and the Transformation of Ba/F3 Cells.

Advances in the Research of JAK2 Abnormalities in Heamatological Disorders

Amino Acid Residue E543 in Jak2 C618r is A Potential Therapeutic Target for Myeloproliferative Disorders Caused by Jak2 C618r Mutation

The Effects of R683S (G) Genetic Mutations on the JAK2 Activity, Structure and Stability.

The Associations of Janus Kinase-2 (jak2) A830g Polymorphism and the Treatment Outcomes in Patients with Acute Myeloid Leukemia

The polymorphism of JAK2 rs56118985 may be a predictive marker of the treatment responses of acute myeloid leukemia patients

Research of gene mutation in acute myeloid leukemia: development and prospect

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia

Association of Janus Kinase 2(jak2) A830g Polymorphism with Acute Leukemia Susceptibility.

Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation

Effects of the I682F Mutation on JAK2's Activity, Structure and Stability

[Inhibitors of JAK2/STAT Signaling Pathway and Hematologic Malignancies-Review].

Gene mutation profile and risk stratification in AML1‑ETO‑positive acute myeloid leukemia based on next‑generation sequencing

Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia

The investigation of mutation and single nucleotide polymorphism of receptor tyrosine kinases and downstream scaffold molecules in acute myeloid leukemia.